Evaluation of Peritoneal Membrane Function After Dapagliflozin Treatment in a Patient Who Had Undergone Peritoneal Dialysis
Kidney and Dialysis · 17.07.2026 · 6 (3) · 49
DOI: 10.3390/kidneydial6030049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney and Dialysis, online erschienen am 17.07.2026. Verfasst von Mahdi Tarabeih und 3 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Peritoneal ultrafiltration failure is a major complication of peritoneal dialysis and a common cause of technique failure often leading to hemodialysis. Chronic exposure to glucose-based dialysate contributes to inflammation, fibrosis, and peritoneal membrane dysfunction. This study evaluated the effects of dapagliflozin on peritoneal membrane function in patients with ultrafiltration failure undergoing continuous ambulatory peritoneal dialysis. In our pre–post observational study, 32 patients with high/high–average peritoneal transport status and ultrafiltration failure received dapagliflozin 10 mg daily for six months. Peritoneal equilibration tests using a 4.25% dextrose solution were performed during early peritoneal dialysis, at ultrafiltration failure, and after treatment. Ultrafiltration volume, dialysate-to-plasma creatinine ratio, dialysate glucose ratio, sodium dip, and clinical/biochemical parameters were assessed. Dapagliflozin treatment was found to be associated with higher ultrafiltration volume (480 mL vs. 90 mL at ultrafiltration failure, p < 0.001), preservation of the intraperitoneal glucose gradient, changes in the dialysate-to-plasma creatinine ratio, and altered sodium dip parameters. Favorable changes were also observed in blood pressure, body mass index, inflammatory markers, hemoglobin, albumin, sodium, bicarbonate, and glycemic indices. No serious adverse events were reported. These findings suggest that dapagliflozin may improve ultrafiltration efficiency and peritoneal membrane function in peritoneal dialysis patients with ultrafiltration failure. Further randomized controlled trials are warranted.
Zitieren
APA
Tarabeih, M., Qaddumi, J., Sawalmeh, O., & Hamadi, S. (2026). Evaluation of Peritoneal Membrane Function After Dapagliflozin Treatment in a Patient Who Had Undergone Peritoneal Dialysis. Kidney and Dialysis, 6(3), 49. https://doi.org/10.3390/kidneydial6030049
Vancouver
Tarabeih M, Qaddumi J, Sawalmeh O, Hamadi S. Evaluation of Peritoneal Membrane Function After Dapagliflozin Treatment in a Patient Who Had Undergone Peritoneal Dialysis. Kidney and Dialysis. 2026;6(3):49. doi:10.3390/kidneydial6030049
BibTeX
@article{Tarabeih2026,
author = {Tarabeih, Mahdi and Qaddumi, Jamal and Sawalmeh, Osama and Hamadi, Sajeda},
title = {Evaluation of Peritoneal Membrane Function After Dapagliflozin Treatment in a Patient Who Had Undergone Peritoneal Dialysis},
journal = {Kidney and Dialysis},
year = {2026},
volume = {6},
number = {3},
pages = {49},
doi = {10.3390/kidneydial6030049}
}
EUVIMED